$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Nordson (NDSN) delivered a strong Q3 beat with robust margins, reaffirmed guidance, and a $500M buyback, highlighting margin resilience and confident capital allocation despite higher leverage.

# Nordson Delivers Strong Q3 Beat with Margin Resilience and Bullish Capital Allocation

---

## Executive Summary

- **Nordson Corporation (NDSN) delivered a robust Q3 performance**, with revenue of **$741.51M** beating consensus by **$18.94M** and adjusted EPS of **$2.73** surpassing expectations by $0.10. All business segments posted year-over-year growth, led by a standout **+32% YoY increase in Medical and Fluid Solutions**.
- **Earnings quality was high**, with a **gross margin of 54.75%** and **net margin of 16.46%**, reflecting strong cost control and pricing power. Management’s operational discipline was evident, supporting both profitability and future growth.
- **Management’s tone was bullish**, emphasizing the benefits of Nordson’s diversified portfolio and “close-to-customer” model. The announcement of an additional **$500M share repurchase authorization** underscores confidence in the company’s outlook and capital allocation strategy.
- **Guidance for FY25 was reaffirmed**, with sales expected between **$2.75B and $2.87B** and EPS in the range of **$9.70 to $10.50**. While sales guidance is slightly below the midpoint, EPS guidance is above, highlighting a focus on margin strength over aggressive top-line growth.
- **Risks include a higher debt-to-equity ratio (0.78)** versus peers, which could pose leverage concerns if not managed prudently. However, **opportunities remain in high-growth segments** and continued capital returns. Notably, recent insider buying signals management’s confidence.
- **Catalyst watch:** Positive after-hours share price reaction suggests the market is responding favorably. Upcoming catalysts include Q4 results and further updates on capital allocation and segment performance.

---

## Performance Snapshot

| Metric                      | Reported   | Consensus  | Surprise   | YoY Change      |
|-----------------------------|------------|------------|------------|-----------------|
| Revenue                     | $741.51M   | $722.57M   | +$18.94M   | +High-single digits |
| Adjusted EPS                | $2.73      | $2.63      | +$0.10     | +Mid-single digits  |
| Gross Margin                | 54.75%     | —          | —          | +Stable/Improved   |
| Net Margin                  | 16.46%     | —          | —          | +Stable/Improved   |
| Medical & Fluid Solutions   | —          | —          | —          | +32% YoY           |
| Debt-to-Equity              | 0.78       | —          | —          | +vs. peers         |
| Price-to-Sales (P/S) Ratio  | 4.44       | —          | —          | +vs. sector        |

---

## Earnings Quality

Nordson’s Q3 results reflect **high earnings quality**, with broad-based revenue growth across all segments and particularly strong performance in Medical and Fluid Solutions. The company’s **gross margin of 54.75%** and **net margin of 16.46%** highlight effective cost management and pricing discipline. There was no evidence of one-off items inflating results, and the margin profile suggests that operational excellence and a diversified product mix are driving sustainable profitability. The company’s ability to maintain margin strength even as sales guidance moderates is a key differentiator.

---

## Management Commentary & Guidance

Management’s commentary was **decidedly bullish**, emphasizing the strength of Nordson’s “close-to-customer” approach and the resilience provided by its diversified portfolio. The reaffirmed FY25 guidance—**sales of $2.75B–$2.87B** and **EPS of $9.70–$10.50**—signals confidence in continued margin expansion, even as top-line growth expectations are tempered. The announcement of a **$500M share repurchase authorization** and recent insider buying further reinforce management’s positive outlook and commitment to shareholder returns.

---

## Key Risks

- **Leverage:** Nordson’s **debt-to-equity ratio of 0.78** is higher than sector peers, raising potential concerns about balance sheet flexibility if macro conditions deteriorate.
- **Cost Pressures:** While margins are currently strong, ongoing inflation in labor, logistics, or raw materials could pressure profitability.
- **Demand Risks:** Any slowdown in key end markets, particularly in Medical and Fluid Solutions, could impact growth momentum.

---

## Expected Market Reaction

Analyst and investor sentiment is expected to be **positive**, as evidenced by the immediate after-hours share price increase. The combination of a revenue and EPS beat, strong margin performance, and aggressive capital returns is likely to drive further interest in the stock. However, some may scrutinize the elevated P/S ratio and leverage metrics for signs of potential overvaluation or risk.

---

## Final Takeaway

**Nordson’s Q3 was a strong quarter**, marked by broad-based growth, margin resilience, and a confident management team. The market may be underappreciating the company’s ability to sustain margins and deliver shareholder returns, even as sales growth moderates. **Key upcoming catalysts** include Q4 earnings and further updates on capital allocation and segment performance. Investors should monitor leverage trends and macroeconomic developments, but the current trajectory supports a constructive outlook for Nordson.

Nordson (NDSN): Margin Strength and Capital Returns Drive Q3 Beat

Nordson (NDSN) is poised for Q3 FY25 outperformance, driven by strong ATS/MFS segment momentum, operational leverage from innovation, and robust backlog growth, with margin expansion likely underestimated by the market.

# Nordson Corporation Q3 FY25 Earnings Outlook: Cautious Optimism Fueled by Segment Momentum and Operational Leverage

## Executive Summary

We maintain a **Bullish** outlook for Nordson Corporation heading into Q3 FY25, underpinned by robust performance in Advanced Technology Solutions (ATS) and Medical & Fluid Solutions (MFS), as well as strong free cash flow conversion. **Q3 revenue is guided at $710M–$750M** (vs. Q2’s $682.9M), with **adjusted EPS expected between $2.55 and $2.75**. Management’s “cautiously optimistic” tone is supported by a **5% QoQ backlog increase** and continued margin expansion in ATS and MFS. However, the market may be underestimating the operational leverage from recent innovation—specifically, the **30% cycle time reduction in semiconductor packaging**—which could drive upside to margin expectations in the coming quarters.

## Recent Trends Signal What’s Next

Nordson’s last two quarters highlight a clear acceleration in revenue and margin stability, particularly in high-growth segments. **Q2 FY25 revenue reached $682.9M** (up from $664.9M in Q1), with **gross margin steady at 54.75%** and **operating margin at 24.7%**. Segment analysis reveals:

- **IPS:** Sales down 8% YoY, margin compressed to 36%
- **MFS:** Sales up 20% YoY, margin improved to 38%
- **ATS:** Organic sales up 18%, margin expanded to 25%

### Quarterly Financial Trend Table

| Quarter    | Revenue ($M) | Gross Margin | Operating Margin | Adj. EPS |
|------------|--------------|--------------|------------------|----------|
| Q3 FY24    | 648.2        | 54.2%        | 23.8%            | $2.28    |
| Q4 FY24    | 670.5        | 54.5%        | 24.1%            | $2.35    |
| Q1 FY25    | 664.9        | 54.6%        | 24.3%            | $2.37    |
| Q2 FY25    | 682.9        | 54.75%       | 24.7%            | $2.42    |

**Trend:** Revenue and margins have shown sequential improvement, with Q3 guidance implying further acceleration.

## Management’s Forward Tone and Positioning

Management’s Q2 call and recent filings reflect a **measured but positive outlook**. CEO Sundaram Nagarajan stated, “We’re seeing early signs of normalization in demand, particularly in ATS and MFS,” and described the company’s posture as “cautiously optimistic for the second half.” This is a notable shift from the prior quarter’s more defensive language, which focused on “navigating persistent macro headwinds.” The current tone signals increased confidence in backlog conversion and segment resilience, while still acknowledging external risks.

## KPI Trends & Upcoming Quarter Drivers

Key performance indicators point to continued strength in Q3:

- **Backlog:** Up 5% QoQ, driven by ATS orders. This supports higher revenue visibility.
- **Free Cash Flow Conversion:** 116% over the last six months, indicating strong operational efficiency.
- **Segment Margins:** ATS margin expanded from 20% to 25% YoY; MFS margin up from 37% to 38%.

### KPI Movement Table

| KPI                | Q2 FY24 | Q1 FY25 | Q2 FY25 | YoY Change | QoQ Change |
|--------------------|---------|---------|---------|------------|------------|
| Backlog ($M)       | 410     | 425     | 446     | +9%        | +5%        |
| FCF Conversion (%) | 108     | 112     | 116     | +8 pts     | +4 pts     |
| ATS Margin (%)     | 20      | 23      | 25      | +5 pts     | +2 pts     |

**Implication:** Backlog growth and margin expansion in ATS/MFS are likely to drive both top-line and bottom-line outperformance in Q3.

## Missed by the Street

A key overlooked signal is the **30% cycle time reduction from the new ASYMTEK Vantage system** (ATS segment), mentioned briefly in the Q2 call. This innovation is poised to materially improve throughput and yield in semiconductor packaging, potentially delivering incremental margin upside not yet reflected in consensus models. Additionally, a recent **$601K insider purchase by a VP** signals internal confidence in near-term performance.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($M) | Adj. EPS | Gross Margin | Key Assumptions                                              |
|----------|--------------|----------|--------------|--------------------------------------------------------------|
| Bull     | 750          | 2.75     | 55%          | Strong ATS/MFS growth, smooth backlog conversion, FX stable  |
| Base     | 730          | 2.65     | 54.5%        | Moderate growth, minor FX/tariff headwinds, IPS stable       |
| Bear     | 710          | 2.55     | 54%          | IPS margin pressure, higher FX/tariff impact, backlog delays |

**Most Likely:** The **Base case** is most probable, given current backlog trends, management’s tone, and segment momentum, but with some caution around IPS and macro risks.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter    | Revenue ($M) | Adj. EPS | Gross Margin | Operating Margin |
|------------|--------------|----------|--------------|------------------|
| Q3 FY24    | 648.2        | 2.28     | 54.2%        | 23.8%            |
| Q4 FY24    | 670.5        | 2.35     | 54.5%        | 24.1%            |
| Q1 FY25    | 664.9        | 2.37     | 54.6%        | 24.3%            |
| Q2 FY25    | 682.9        | 2.42     | 54.75%       | 24.7%            |

### KPI Movement Table

| KPI                | Q2 FY24 | Q1 FY25 | Q2 FY25 | YoY Change | QoQ Change |
|--------------------|---------|---------|---------|------------|------------|
| Backlog ($M)       | 410     | 425     | 446     | +9%        | +5%        |
| FCF Conversion (%) | 108     | 112     | 116     | +8 pts     | +4 pts     |
| ATS Margin (%)     | 20      | 23      | 25      | +5 pts     | +2 pts     |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand, particularly in ATS and MFS.”**  
   – Q2 FY25 Earnings Call  
   *Signals improving end-market conditions and supports Q3 growth guidance.*

2. **“Our backlog increased 5% sequentially, providing strong visibility into the next quarter.”**  
   – Q2 FY25 Earnings Call  
   *Indicates robust order momentum, especially in ATS.*

3. **“We remain cautiously optimistic for the second half, balancing growth opportunities with macro uncertainties.”**  
   – Q2 FY25 Earnings Call  
   *Reflects a more constructive tone versus prior quarters.*

4. **“The ASYMTEK Vantage system has reduced cycle times by 30%, enhancing throughput for our semiconductor customers.”**  
   – Q2 FY25 Earnings Call  
   *Highlights a potentially underestimated margin driver.*

5. **“IPS continues to face volume pressure, and we are focused on cost containment to protect margins.”**  
   – Q2 FY25 Earnings Call  
   *Acknowledges ongoing risk in the IPS segment.*

6. **“Our free cash flow conversion remains above 110%, supporting continued investment and shareholder returns.”**  
   – Q2 FY25 Earnings Call  
   *Underscores operational efficiency and capital flexibility.*

7. **“We are monitoring FX and tariff impacts closely, but our diversified portfolio provides resilience.”**  
   – Q2 FY25 Earnings Call  
   *Points to external risks but also to the company’s risk mitigation strategy.*

---

**In summary:** Nordson enters Q3 FY25 with strong segment momentum, operational leverage, and a cautiously optimistic management stance. While IPS remains a risk, innovation and backlog growth in ATS and MFS are likely to drive results above consensus expectations.

Nordson (NDSN): Q3 Margin Upside from Segment Strength